ArticlePloS one2020

Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.

Chiara Parravicini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.